#INDV

3 days ago

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering Indivior (Nasdaq: INDV) priced an upsized $450.0 million offering of 0.625% convertible senior notes due 2031, with a 30-day option to purchase an additional $50.0 million.Net proceeds are estimated at approximately $437.7 million (or ~$486.4 million if option exercised). The initial conversion price is about $41.66 per share, a ~35.0% premium to the March 12, 2026 closing price.

#INDV Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

www.stocktitan.net/news/INDV/indivior-price...

0 0 0 0

StockTitan

@stocktitan.net

4 days ago

Indivior Announces Proposed Convertible Senior Notes Offering Indivior (Nasdaq: INDV) intends to offer $400 million aggregate principal amount of convertible senior notes due 2031, with a 30-day option for an additional $60 million. Notes will be senior, unsecured, pay semi-annual interest, and may be converted for cash and/or shares.Indivior expects to use ~$239 million of net proceeds plus ~$102 million cash to repay its term loan and credit facility, up to ~$75 million to repurchase common stock concurrently, and the remainder for general corporate purposes.

#INDV Indivior Announces Proposed Convertible Senior Notes Offering

www.stocktitan.net/news/INDV/indivior-annou...

0 0 0 0

StockTitan

@stocktitan.net

4 days ago

New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder Indivior (NASDAQ: INDV) reported a retrospective real-world study published March 11, 2026 linking 12-month adherence to SUBLOCADE (monthly injectable buprenorphine) with substantially lower healthcare use and costs in commercially insured patients with opioid use disorder.Key result: SUBLOCADE-adherent patients had $15,017 (42%) lower annual non-MOUD medical costs versus patients adherent to other MOUD ($35,761 vs $50,778), plus the lowest inpatient, ED, and detox utilization. Study limitations include observational claims data and COVID-19 overlap.

#INDV New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

www.stocktitan.net/news/INDV/new-study-show...

0 0 0 0

StockTitan

@stocktitan.net

2 weeks ago

Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results Indivior (Nasdaq: INDV) reported Q4 and full‑year 2025 results, including record total SUBLOCADE net revenue of $252M (Q4) and $856M (FY), GAAP net income of $102M (Q4) and $210M (FY), and adjusted EBITDA of $142M (Q4) and $428M (FY). The company entered Phase II of its Action Agenda, launched a nationwide DTC campaign, completed U.S. redomiciliation, paid $295M to resolve a legacy DOJ matter, and authorized a $400M share repurchase program. 2026 guidance: net revenue $1,125M–$1,195M; total SUBLOCADE $905M–$945M; adjusted EBITDA $535M–$575M.

#INDV Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results

www.stocktitan.net/news/INDV/indivior-repor...

0 0 0 0

StockTitan

@stocktitan.net

1 month ago

Indivior Announces Completion of Redomiciliation to the United States Indivior (Nasdaq: INDV) completed redomiciliation from the United Kingdom to the United States effective Jan 26, 2026. A new Delaware parent, Indivior Pharmaceuticals, Inc. (IPI), is now the parent and Indivior PLC was renamed Indivior Ltd. Shareholders received one IPI common share for each Indivior PLC ordinary share as of the scheme record date, and Indivior common stock remains listed on Nasdaq under INDV. IPI is now a U.S. domestic issuer subject to SEC reporting and Nasdaq exchange rules. The redomiciliation was approved at an extraordinary general meeting on Dec 11, 2025.

#INDV Indivior Announces Completion of Redomiciliation to the United States

www.stocktitan.net/news/INDV/indivior-annou...

0 0 0 0

Eaves

@joineaves.bsky.social

2 months ago

If there’s one trade to pay attention to…

Indivior just attracted elite capital for the first time ever:

• George Soros: $49M (New)
• Ken Griffin: $54M (+12,292%)
• Howard Marks: $11M (+2,242%)

Already +190% YTD.
Something’s happening.

$INDV #INDV

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

2 months ago

This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table | The Motley Fool When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.

#INDV #47a0e095-6c3e-4414-bf8a-e8b054589c20 #coveragefilings

Origin | Interest | Match

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Indivior Announces Inclusion in the S&P SmallCap 600® Index Indivior (Nasdaq: INDV) announced it was added to the S&P SmallCap 600 index, effective December 22, 2025. The company said the inclusion aligns its capital markets presence with a sharpened U.S. business profile and supports growth of SUBLOCADE, its first‑in‑class long‑acting injectable for moderate to severe opioid use disorder.The S&P SmallCap 600 tracks 600 U.S. small‑cap companies with market capitalizations generally between $1.2 billion and $8.0 billion and applies liquidity and viability criteria for inclusion.

#INDV Indivior Announces Inclusion in the S&P SmallCap 600® Index

www.stocktitan.net/news/INDV/indivior-annou...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

New Research Unveils Promising Results of Extended-Release Buprenorphine in Fighting Opioid Use Disorder A recent clinical trial reveals that both doses of extended-release buprenorphine significantly reduce opioid use among high-risk individuals, showcasing the need for innovative treatment strategies.

New Research Unveils Promising Results of Extended-Release Buprenorphine in Fighting Opioid Use Disorder #USA #Richmond #opioid_use_disorder #Buprenorphine #INDV

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations Indivior (Nasdaq: INDV) reported results from a randomized, double-blind trial showing monthly SUBLOCADE extended-release buprenorphine at both 100 mg and 300 mg produced rapid, clinically meaningful reductions in opioid use and improved abstinence in people with moderate-to-severe opioid use disorder.Participants reduced opioid use from >43 instances/week at screening to 300-mg maintenance dose achieved significantly higher abstinence in participants with high-frequency fentanyl use. Both doses were well tolerated with no new safety signals; injection-site reactions were more common with 300 mg but were mild-to-moderate and not linked to discontinuation. The post-hoc findings were exploratory and not pre-specified.

#INDV New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations

www.stocktitan.net/news/INDV/new-study-show...

1 0 0 0

StockTitan

@stocktitan.net

3 months ago

Indivior Concludes Legacy U.S. Department of Justice Matter Indivior (Nasdaq: INDV) announced on November 20, 2025 that it has concluded a legacy U.S. Department of Justice matter by paying in full the outstanding obligation of $295 million. With receipt of the payment by the DOJ, the resolution agreement will be terminated.The company said the payment was funded with cash on hand, and management described the milestone as removing a significant liability and simplifying the company's capital structure while reaffirming its compliance commitments.

#INDV Indivior Concludes Legacy U.S. Department of Justice Matter

www.stocktitan.net/news/INDV/indivior-concl...

0 0 0 0

Market Wire News

@marketwirenews.com

3 months ago

BREAKING NEWS: ( NASDAQ: #INDV ) Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

#INDV Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

www.stocktitan.net/news/INDV/indivior-repor...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment Rapid induction with SUBLOCADE ® showed higher treatment retention rates compared to standard induction, particularly among fentanyl-positive participants. RICHMOND, Va., Oct. 15, 2025/ PRNewswire/-- Indivior PLC this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two approaches were...

#INDV Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment

www.stocktitan.net/news/INDV/clinical-evide...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Major Pharma Shift: Indivior Abandons UK Home for Full US Presence, Creating New Delaware Parent Company Indivior will establish US-based Indivior Pharmaceuticals Inc as new parent company, requiring 75% shareholder approval. Plan includes 1:1 share exchange, maintaining INDV ticker on Nasdaq.

#INDV Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation

www.stocktitan.net/news/INDV/indivior-propo...

0 0 0 0

Value The Markets

@valuethemarkets.bsky.social

7 months ago

Indivior is back in the spotlight.

Strong Q2 results, growing Sublocade sales, and a raised outlook sent the stock soaring ~21%. Is this the turnaround investors have been waiting for?

📖 Read more → buff.ly/RF6ekLs

#INDV #StockNews #Earnings

---
Disclaimer: Info only. DYOR. buff.ly/tNWBvJD

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

Indivior (INDV) Q2 EPS Jumps 104% | The Motley Fool

#INDV #c84106a8-1ecc-4dc5-9c98-95ec8b15a2a6 #data-news

Origin | Interest | Match

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

7 months ago

Most Searched, Thursday July 31, 2025 – Crystal Equity Research

Most searched small-cap stocks, Thu Jul 31st - #EOSE #ONCO #LIDR #TROX #FUBO #HIVE #PAPL #PBM #WULF #INDV #DNN #OPEN #WRD #UUUU #LUNR #ESPR #CERS #APLD #ALHC #AI - More: crystalequityresearch.com/most-searche... - #smallcap

0 1 0 0

StockTitan

@stocktitan.net

7 months ago

Indivior Earnings Beat: Revenue Hits $302M as Company Boosts Full-Year Outlook by $65M Q2 earnings exceed expectations with SUBLOCADE growth driving guidance raise. Adjusted EBITDA outlook increased to $275M-$300M range. See full financial details.

#INDV Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance

www.stocktitan.net/news/INDV/indivior-repor...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Indivior Added to Russell 2000: SUBLOCADE Maker Sees 85% Revenue from US Market Pharmaceutical leader Indivior gains Russell indexes membership amid strong US market presence. Discover how SUBLOCADE drives 85% of revenue. See growth details.

#INDV Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes

www.stocktitan.net/news/INDV/indivior-annou...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users Indivior (NASDAQ: INDV) presented new data at CPDD showing that higher doses (300mg) of SUBLOCADE, their buprenorphine extended-release treatment, may improve outcomes for opioid use disorder (OUD) patients with heavy fentanyl use. While not statistically significant compared to 100mg doses, the 300mg maintenance dose showed clinically meaningful improvements in opioid abstinence. Both dosing regimens demonstrated significant reductions in opioid use, from 40 instances weekly to fewer than 3 by Week 3, sustained through Week 38, with no new safety concerns. The company also presented research on treatment barriers for American Indian/Alaska Native populations, who face disproportionate OUD rates. A claims analysis of 75,000+ AI/AN patients revealed that 73.1% used non-IHS providers, and MOUD-treated patients showed lower emergency department visits.

#INDV Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

www.stocktitan.net/news/INDV/indivior-prese...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks overbought with declining relative strength, Mon Jun 9th - #GRPN #INDV #LYRA #SGHT #ABVX #FMST #MHUA #ROMA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained Indivior PLC (INDV) has announced plans to cancel its secondary listing on the London Stock Exchange (LSE) while maintaining its primary Nasdaq listing, effective July 25, 2025. This strategic decision follows the company's transition to a U.S. primary listing and reflects that over 80% of revenue comes from the U.S. market, primarily driven by SUBLOCADE. The move is supported by key factors: approximately 75% of trading volume now occurs on Nasdaq, over 70% of shareholders are U.S.-based, and it will reduce costs and complexity of maintaining dual listings. The last trading day on LSE will be July 24, 2025. The UK Takeover Code will continue to apply for two years after delisting. The decision requires no shareholder approval and is expected to have no impact on direct holders of Ordinary Shares or those holding through DTC brokers.

#INDV Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

www.stocktitan.net/news/INDV/indivior-annou...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Indivior Taps Former Endo Executive to Drive SUBLOCADE Growth Strategy Former Endo CCO Patrick Barry brings 30-year pharma expertise to lead Indivior's commercial strategy. Key focus: expanding SUBLOCADE treatment reach. See growth plans.

#INDV Indivior Announces Patrick Barry as Chief Commercial Officer

www.stocktitan.net/news/INDV/indivior-annou...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Mon Mar 10th - #NOEM #OPTX #PFS #OFS #MGIC #LFVN #INDV #HDSN #DRIO #MTUS #KLG #BGS #AIV - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Can Former Collegium CEO Joseph Ciaffoni Transform Indivior's Addiction Treatment Business? Former Collegium Pharmaceutical CEO brings 30+ years experience to lead Indivior's next growth phase in addiction treatment market with smooth transition planned.

#INDV Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

www.stocktitan.net/news/INDV/indivior-annou...

0 0 0 0

marketshareai.uk

@marketshareai.bsky.social

1 year ago

📈 Indivior's SUBLOCADE approved for rapid initiation & alternative injection sites, expanding treatment options for opioid use disorder. $INDV #Healthcare

Get ahead with today's top stories 👇

https://marketshareai.uk/news/lse/indv/1783Y

#INDV #AIM #FTSE

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Game-Changing OUD Treatment Update: SUBLOCADE Now Offers 1-Hour Start Protocol New FDA-approved protocol reduces SUBLOCADE treatment initiation from one week to just one hour, with multiple injection sites and improved patient retention.

#INDV Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

www.stocktitan.net/news/INDV/indivior-annou...

0 0 0 0

Posts tagged #INDV